Skip to content

Clinical trials

Prostatic Neoplasms trials in China with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Phase: Not applicable Country / region: China Clear all

95 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20131
20153
20163
20172
20187
20194
20205
20218
202211
202310
202415
202517
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status37
Recruiting27
Completed11
Not yet recruiting10
Active, not recruiting5
Enrolling by invitation2
Suspended1
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking University First Hospital12
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School7
Shanghai East Hospital6
Fudan University4
Cancer Institute and Hospital, Chinese Academy of Medical Sciences3
Changhai Hospital3
Peking University Cancer Hospital & Institute3
Qilu Hospital of Shandong University3
Shanghai Proton and Heavy Ion Center3
Xijing Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms95
Disease9
Urinary Bladder Neoplasms5
Adenocarcinoma2
Anxiety Disorders2
Carcinoma, Renal Cell2
Glioma2
Kidney Neoplasms2
Neoplasm Metastasis2
Adrenal Gland Neoplasms1

Trials

Showing 1 to 25 of 95. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.